Account
Watchlists
Bookmarks
Pricing
Home
Dashboard
Ask Portfolio
Discovery
Timeline
Toolkit
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
Fabtech Technologies Limited is a global company specializing in comprehensive turnkey engineering solutions for the pharmaceutical, biotechnology, and healthcare industries. With a footprint in over 62 countries, particularly in emerging economies, the company provides end-to-end services from design to certification for aseptic manufacturing facilities. Fabtech operates as part of the Fabtech Group and utilizes an asset-light, integrated business model, procuring key equipment from related group entities. It leverages its proprietary in-house software, 'FabAssure', for efficient project management, planning, and execution, enhancing transparency and operational control.
Opening Date
Sep 29, 2025
Closing Date
Oct 01, 2025
Listing Date
Oct 07, 2025
IPO Type
Mainboard
IPO Status
Closed
Issue Size
230.35 Cr
Fresh Issue
230.35 Cr
Offer for Sale
—
Price Band
₹181 - ₹191
Lot Size
75
Our Company proposes to utilize the Net Proceeds from the Issue towards funding the following objects:
Funding the working capital requirements of our Company to support business operations and the execution of future projects in Fiscals 2026 and 2027.
Pursuing inorganic growth initiatives through strategic acquisitions of companies engaged in manufacturing process equipment and other critical components in India, the United Arab Emirates, Saudi Arabia, and Egypt.
Funding general corporate purposes, which may include meeting operational expenses, strengthening marketing capabilities, and other strategic initiatives as approved by the Board.
P/E Ratio
—
EPS
—
ROE
30.46%
ROCE
24.46%
RONW
26.83%
Debt to Equity Ratio
0.32
PAT Margin
13.83%
EBITDA Margin
14.07%
P/B
3.57
Acts as a key turnkey engineering solution provider with comprehensive, integrated start-to-finish service offerings for the pharma and biotech sectors.
Operates on an asset-light and integrated business model, leveraging related group entities for equipment procurement, which allows for scalability and cost-efficiency.
Utilizes proprietary in-house software, 'FabAssure', for advanced project management, enabling real-time monitoring, efficient execution, and enhanced transparency.
Possesses a diversified order book across various geographies and has a proven track record of executing complex projects in challenging environments.
Significant revenue concentration from a limited number of large projects, making financial performance vulnerable to delays or cancellations of key contracts.
Heavy reliance on related group entities for procuring a significant portion of equipment, which can lead to potential conflicts of interest and supply chain dependencies.
Geographical concentration of projects in the GCC and MENA regions, exposing the business to geopolitical instability and economic fluctuations in these areas.
Predominantly operates on fixed-price contracts, which exposes the company to risks of cost overruns and potential reduction in profit margins.
Expansion in existing core regions like GCC, MENA, and ECO by establishing a stronger local presence through overseas subsidiaries or joint ventures.
Increasing government clientele in the African region by bidding for public healthcare infrastructure projects, capitalizing on the growing need for pharmaceutical facilities.
Pursuing inorganic growth through strategic acquisitions in key markets such as India, UAE, Saudi Arabia, and Egypt to enhance manufacturing capabilities and market penetration.
Diversifying the customer base by targeting non-pharmaceutical sectors like nutraceuticals and GMP-certified fast-moving consumer goods (FMCG).
Exposure to political, economic, and regulatory changes in multiple international jurisdictions, which can adversely affect project execution and financial stability.
Increasing competition from other domestic and international turnkey engineering solution providers in the pharmaceutical capex space.
Potential disruptions from geopolitical tensions, regional conflicts, and supply chain issues in key operating regions like the Middle East and Africa.
Changes in global economic conditions, such as inflation or interest rate hikes, which can impact clients' capital expenditure plans and demand for new projects.